×
TuHURA Biosciences Common Stock Net 2010-2024 | HURA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
TuHURA Biosciences common stock net from 2010 to 2024. Common stock net can be defined as the value of common equity ownership.
View More
TuHURA Biosciences Common Stock Net 2010-2024 | HURA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
TuHURA Biosciences common stock net from 2010 to 2024. Common stock net can be defined as the value of common equity ownership.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$171.8B
Vertex Pharmaceuticals (VRTX)
$122.6B
Gilead Sciences (GILD)
$109.8B
Bristol Myers Squibb (BMY)
$107B
Regeneron Pharmaceuticals (REGN)
$106.1B
CSL (CSLLY)
$96.1B
GSK (GSK)
$78.8B
Alnylam Pharmaceuticals (ALNY)
$38.1B
Argenex SE (ARGX)
$34B
Biogen (BIIB)
$27.1B
BioNTech SE (BNTX)
$26.4B
Illumina (ILMN)
$22.9B
BeiGene (BGNE)
$21.5B
Moderna (MRNA)
$20.5B
Genmab (GMAB)
$15.1B
BioMarin Pharmaceutical (BMRN)
$13.4B
Exact Sciences (EXAS)
$13B
Insmed (INSM)
$12.7B
Incyte (INCY)
$12.6B
Vaxcyte (PCVX)
$12.6B
Sarepta Therapeutics (SRPT)
$12.2B
Bio-Techne Corp (TECH)
$11.1B
QIAGEN (QGEN)
$9.6B
Bio-Rad Laboratories (BIO.B)
$9.3B
Roivant Sciences (ROIV)
$8.7B
Exelixis (EXEL)
$8.2B
Legend Biotech (LEGN)
$8.2B
Intra-Cellular Therapies (ITCI)
$8.1B
Repligen (RGEN)
$8.1B
Revolution Medicines (RVMD)
$7.9B